|
Teva’s Neupogen ‘Biosimilar’ Poised to Take Half of Market by 2016: Analyst
Teva has scored a victory on the road to biosimilar approvals with the FDA’s OK of its copycat version of Amgen’s Neupogen, a win that could halve Amgen’s U.S. market share by the end of 2016, analysts say.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives